Initial management of lower-risk myelodysplastic syndromes/neoplasms that require treatment

Refer to related UpToDate material for evaluation, diagnosis, classification, and prognostic risk in patients with MDS. Treatment is individualized, and all patients should receive transfusions, treatment/prophylaxis for infections, and other supportive care as needed. Enrollment in a clinical trial is encouraged.

BM: bone marrow; EPO: erythropoietin; ESA: erythropoiesis-stimulating agent; IST: immunosuppressive therapy; MDS: myelodysplastic syndromes/neoplasms; PNH: paroxysmal nocturnal hemoglobinuria; TPO-RA: thrombopoietin receptor agonist.

* IST is acceptable for patients with ≥2 cytopenias and clinicopathologic features that favor a good response to IST.

¶ Luspatercept is also acceptable for initial therapy.

Δ Azacitidine or decitabine are acceptable options for initial treatment.

Graphic 146658 Version 1.0

خرید پکیج

Initial management of lower-risk myelodysplastic syndromes/neoplasms that require treatment